Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02954406
Title A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | CAN

Facility Status City State Zip Country Details
University of Arizona Cancer Center, Tucson Tucson Arizona 85724 United States Details
University of California San Diego (UCSD) - Moores Cancer Center La Jolla California 92093 United States Details
Cedars-Sinai Medical Center (CSMC) - Samuel Oschin Comprehensive Cancer Institute West Hollywood California 90048 United States Details
University of Louisville Kentucky James Graham Brown Cancer Center Louisville Kentucky 40202 United States Details
Center for Cancer and Blood Disorders Bethesda Maryland 20817 United States Details
Tufts Medical Center Boston Massachusetts 02111 United States Details
Henry Ford Hospital Detroit Michigan 48202-2608 United States Details
NYU Langone Medical Center - NYU Medical Oncology Associates New York New York 10016-4744 United States Details
University of North Carolina - Lineberger Comprehensive Cancer Center Chapel Hill North Carolina 27514 United States Details
University Hospitals of Cleveland Cleveland Ohio 44106 United States Details
West Virginia University Morgantown West Virginia 26506 United States Details
Queen Elizabeth II Health Sciences Centre Halifax Nova Scotia B3H 2Y9 Canada Details
McGill University - Jewish General Hospital Montreal Quebec H3T 1E2 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field